Trial reportOpen forum infectious diseases2026
Oseltamivir for Treatment of Influenza Among Outpatient Veterans: Target Trial Emulation.
Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of oseltamivir for the treatment of nonsevere influenza in preventing progression to severe illness is uncertain. Methods: In a target trial emulation of veterans who presented to emergency departments in the Veterans Health Administration (VHA) and tested positive for influenza between 1 October 2022-31 January 2023, or 1 December 2023-31 March 2024, we compared treatment with oseltamivir versus no antiviral treatment within 6 hours of a positive influenza test. Following inverse probability of treatment weighting, we calculated cumulative incidence, risk differences (RDs), and risk ratios (RR) for hospitalization and intensive care unit (ICU) admission at 10 days and death at 30 days. Results: Among 28 920 veterans, 25 025 (87%) were male with median age 61 (45-72) years. Oseltamivir-treated patients had a lower risk of hospitalization (3.81% vs 6.96%; RD, -3.15% [95% confidence interval {CI}, -3.70% to -2.60%]; RR, 0.55 [CI, .49-.61]) and ICU admission (0.65% vs 1.38%; RD, -0.73% [CI, -.98% to -.48%]; RR, 0.47 [CI, .35-.62]) than untreated persons. The largest absolute risk reductions in hospitalization occurred in patients ≥65 years (RD, -5.21% [CI, -6.39% to -4.04%]) and among those prescribed treatment within 3 hours of testing positive (RD, -5.77% [CI, -6.54% to -5.00%]). Overall incidence of death was similar between groups (RD, 0.10% [CI -.07%-.27%]). Conclusions: Oseltamivir reduced the risk of hospitalization and ICU admission but not death. Substantial reductions in hospitalization risk were observed in older adults and patients prescribed treatment within 3 hours of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.